The Synairgen share price slumps! Here’s what I’d do now

The Synairgen share price has slumped following the publication of its latest trial results. This Fool isn’t planning to buy the decline.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Synairgen (LSE: SNG) share price has crumbled in value in early deals this morning. The stock is off nearly 8%, at the time of writing. 

To put this decline into perspective, over the past 12 months, shareholders have seen a return of 126%. Moreover, since the beginning of 2020, the stock has risen by more than 2,000%. 

However, past performance should never be used as a guide to future potential. Just because the Synairgen share price has produced considerable returns in the past doesn’t mean it’ll continue to outperform. 

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

That has become painfully clear today after the firm published results from its phase II trial of inhaled interferon beta in Covid-19 patients.

Positive results 

Today’s update from the business was a positive one. According to Richard Marsden, CEO of Synairgen, the trial findings show that the “SNG001 treatment led to a threefold likelihood of recovery to ‘no limitation of activities’ in the markedly/severely breathless population compared to those on placebo in the home and hospital setting.

SNG001 is Synairgen’s formulation containing interferon beta for nebulisation. This allows delivery directly into patients’ lungs.

Some studies have shown that Covid-19 suppresses the natural production of interferon beta. The virus can also prevent the induction of antiviral responses by infected cells. Synairgen’s work appears to show that its SNG001 formulation containing interferon beta can help overcome this problem. 

However, the company is still a long way from commercialising the product. The latest findings still need to be peer-reviewed. It’s also in the process of completing a phase III trial. After that, regulators will need to approve the product.

Considering the volume of work still required, there’s no guarantee this product will ever successfully make it to market. I think that’s the most significant risk overhanging the Synairgen share price right now. 

Synairgen share price decline 

It’s difficult to tell exactly why the Synairgen share price has declined so substantially today. However, it looks to me as if the market is starting to become concerned about the firm’s valuation. 

The company’s current market capitalisation stands at £308m, which seems to me to be a lot, considering the success of SNG001 is far from guaranteed. 

Of course, on the other hand, if the treatment successfully makes it through the next trial stage and is approved by medical regulators, the market could be substantial. In this best-case scenario, the Synairgen share price may be incredibly undervalued at current levels.

Despite this, I’m not a buyer of the stock today. I think the company’s future is incredibly uncertain. Until we have more information on the SNG001 treatment, there’s no guarantee whatsoever this will ever be a sustainable business.

This is just my own personal preference as I don’t like to invest in companies still in the development stage. However, other investors may be comfortable taking on this level of risk. 

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won’t want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we’re giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British pound data
Investing Articles

£10,000 invested in Marks and Spencer shares before the cyberattack is now worth…

A hacking group's ransomware attack is hurting Marks and Spencer shares. Here's why investors should now tread cautiously with the…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Should Berkshire Hathaway still be on my list of shares to buy?

As shares in Warren Buffett’s company fall on news of the CEO’s retirement, is this an opportunity to buy or…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

1 FTSE 100 retail stock investors should consider right now

Ken Hall has his eye on J Sainsbury as a shareholder-friendly FTSE 100 retail stock that is trading cheaply compared…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Legal & General shares yield 9% but trade at a 10-year low! Are they a deadly value trap?

Harvey Jones loves all the dividend income he's getting from Legal & General shares, but he's starting to get a…

Read more »

Pakistani multi generation family sitting around a table in a garden in Middlesbourgh, North East of England.
Investing Articles

£5,000 invested in Barclays shares a month ago is now worth…

Barclays has been a terrific investment over the past month as well as over the last year. But can its…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

What should we do about Berkshire Hathaway stock now Warren Buffett is retiring?

Warren Buffett is to step down from Berkshire Hathway at the end of the current year, after an amazing 60…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

My favourite S&P 500 growth stock is on fire! What’s going on?

Ben McPoland has been very pleased with the performance of this S&P 500 stock in 2025. But is it still…

Read more »

US Tariffs street sign
Investing Articles

Are Glencore shares a bargain after falling 33%?

With the Glencore share price in freefall decline, Andrew Mackie assesses whether now is the time for investors to consider…

Read more »